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Abstract
Elevated circulating cholesterol is a systemic risk factor for cardiovascular disease and metabolic syndrome, however the
manner in which the normal prostate responds to variations in cholesterol levels is poorly understood. In this study we
addressed the molecular and cellular effects of elevated and suppressed levels of circulating cholesterol on the normal
prostate. Integrated bioinformatic analysis was performed using DNA microarray data from two experimental formats: (1)
ventral prostate from male mice with chronically elevated circulating cholesterol and (2) human prostate cells exposed
acutely to cholesterol depletion. A cholesterol-sensitive gene expression network was constructed from these data and the
transcription factor ATF3 was identified as a prominent node in the network. Validation experiments confirmed that
elevated cholesterol reduced ATF3 expression and enhanced proliferation of prostate cells, while cholesterol depletion
increased ATF3 levels and inhibited proliferation. Cholesterol reduction in vivo alleviated dense lymphomononuclear
infiltrates in the periprostatic adipose tissue, which were closely associated with nerve tracts and blood vessels. These
findings open new perspectives on the role of cholesterol in prostate health, and provide a novel role for ATF3, and
associated proteins within a large signaling network, as a cholesterol-sensing mechanism.
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Introduction
The human prostate is subject to a variety of pathologic
conditions and syndromes that are not well understood in
molecular terms. Most investigators have concluded that prostate
health, particularly with respect to prostate cancer, is susceptible to
lifestyle influences [1]. The association with lifestyle likely reflects a
complex interplay between genetic, epigenetic, biochemical and
metabolic processes. This is particularly evident in the US where
sedentary habits and an obesogenic diet are now widespread.
Accumulating evidence indicates that heart disease, diabetes and
metabolic syndrome are associated with increased risk or severity
of lower urinary tract symptoms (LUTS) [2–4].
Cholesterol, and structurally related lipids, are critical in
membrane assembly and integrity. All eukaryotic cell membranes
have cholesterol, ergosterol, or a phytosterol as a major membrane
component. Cholesterol is one of the key regulators of membrane
dynamics, a role tied to its tendency to facilitate the close packing of
saturated acyl chains of membrane phospholipids, thereby stabiliz-
ing local membrane structure. Consequently, membrane compart-
mentalization into functional subdomains influenced by cholesterol
concentrationprovidesforpost-translationalcontroloverimportant
signaltransductionpathways.Theprostatesynthesizeshighlevelsof
cholesterol,atsimilarratestotheliver,andtheprostateaccumulates
cholesterol deposits with age [5]. Recent evidence from pre-clinical
modelshasdemonstratedaroleforcholesterolinsignaltransduction
in prostate cancer cells and tissues [6,7], as well as in intraprostatic/
intratumoral steroidogenesis [8] consistent with epidemiologic
studies indicating that high circulating cholesterol promotes
aggressive forms of the disease [9–12].
Normal tissues sense and respond to variations in circulating
cholesterol. The adult prostate gradually loses the ability to
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accumulation of excess intraprostatic cholesterol [5]. The degree
or manner of the effect of this accumulation on prostate physiology
is poorly understood. One community-based cohort study found a
4-fold increased risk of benign prostatic hyperplasia (BPH) among
diabetic men with low density lipoprotein (LDL) cholesterol in the
highest tertile in comparison to men in the lowest tertile [13]. A
recent study from our group demonstrated that age-related
prostate enlargement in the Syrian 87.20 hamster was dependent
on the presence of cholesterol in the diet, and could be reversed
with ezetimibe, a specific inhibitor of cholesterol absorption from
the intestine [14]. However, our understanding of the effects of
elevated cholesterol and hypocholesterolemic drugs on the
prostate is limited. It is not known, for example, whether
hypercholesterolemia elicits physiologic, metabolic, or biochemical
changes in the prostate that predispose toward disease.
In the present study we attempted to uncover a cholesterol-
sensitive signaling network in the normal prostate of the mouse
and human prostate cells using a systems approach. Our findings
indicate that the prostate responds to variations in circulating
cholesterol levels by altering cholesterol tissue content, cell
proliferation rate and gene expression. Evidence also suggests that
hypocholesterolemia may suppress prostatic inflammation. Our
findings provide the first broad look at the manner in which the
normal prostate responds to changes in circulating cholesterol.
Materials and Methods
Reagents
Heat-inactivated fetal bovine serum (FBS) and Lipofectamine
2000 were from Invitrogen (Carlsbad, CA). Protease inhibitor
cocktail tablets were from Roche Diagnostics (Basel, Switzerland).
The Micro BCA protein assay kit was obtained from Pierce
(Rockford, IL). Coomassie Blue R-250 staining solution and
destaining solution were from Bio-Rad (Hercules, CA). Small
interfering RNAs (siRNAs) against ATF3 and NON-TARGET
controls were from Dharmacon (Chicago, IL). 4’,6-diamidino-2-
phenylindole (DAPI) was purchased from Vector Laboratories
(Burlingame, CA). Antibodies against ATF3 and b-actin were
purchased from Santa Cruz Biotechnology, Sigma-Aldrich (St.
Louis, MO) and Cell Signaling Technology (Danvers, MA).
Antibody against Cy3-conjugated AffiniPure goat anti-rabbit IgG,
Fc fragment specific was obtained from Jackson Immuno Research
(West Grove, PA). All other reagents were obtained from Sigma-
Aldrich or Promega (Madison, WI).
Animal Maintenance and Diet
Male SCID and C57BL/6 mice (5–6 wk old) were obtained
from the Massachusetts General Hospital and Jackson Labs,
respectively. All mice were maintained on a low fat, no cholesterol
diet (LFNC) (Research Diets, New Brunswick, NJ diet # D12102),
equivalent to normal mouse chow, but without lot to lot variation
for 2 weeks to normalize cholesterol levels, after which mice were
divided into individual diet groups. C57BL/6 mice were divided
into 3 diet groups (n=18/group): hypocholesterolemic (Hypo)
(LFNC + ezetimibe–30mg/kg/day; Schering-Plough, New Bruns-
wick, NJ) added to the food), normocholesterolemic (Normo)
(LFNC diet) or hypercholesterolemic (Hyper) (high fat, high
cholesterol (HFHC) diet) (Research Diets, diet # D12108). SCID
mice were grouped into 2 diet groups; Hyper and Normo. Animals
were maintained on the respective diets for 4 months. Animals
were housed in compliance with Children’s Hospital Boston’s
animal care and use policies. All procedures were approved by
IACUC under protocols A07-06-084 and 07-08-1503. Terminal
bleeds were taken for liver function testing and serology by cardiac
puncture. Prostates were removed and divided into individual
anatomic lobes, i.e. ventral (VP), dorsal lateral (DLP) and anterior
(AP) under a dissecting microscope, and either placed in OCT
solution (Tissue-Tek, Torrance, CA) or in formalin for paraffin
embedding [15].
Immunohistochemistry and Immunofluorescence Cell
Staining
4-mm cryostat-obtained tissue sections were mounted on Super-
frost/Plus microscope slides and kept at –80uC before use. Frozen
sections were kept at RT for 1 min, followed by 3X washes in
PBS. Fixation was done with Permeabilization Solution (BD
Bioscience, San Diego, CA) for 15 min. After 1 h blocking with
3% BSA/PBS solution, slides were incubated for 12 h at 4uC with
specific antibodies, followed by incubation with HRP-conjugated
secondary IgG for 30 min at RT. After washing with PBS (3X), 3-
3’ diaminobenzidine (DAB) substrate chromogen solution (Envi-
sion Plus Kit, Dako Corp) was applied. The reaction was
monitored by microscopy and was terminated when properly
developed. Nuclei were counterstained with Meyer’s hematoxylin
and slides were analyzed using an Axioplan 2 microscope (Carl
Zeiss MicroImaging, Inc. Thornwood, NY). Paraffin slides were
dried at 60uC for 2 h before immunohistochemical staining. After
deparaffinization, rehydration and depletion of endogenous
peroxidase activity as described [15], tissue was stained with
specific antibodies against Ki-67 (1:3000, Abcam, Cambridge,
MA) and ATF3 (1:100, Santa Cruz Biotechnology, Santa Cruz,
CA). For immunofluorescence staining, slides were incubated with
antibodies, followed by incubation with Cy3, or FITC-conjugated
secondary Abs (Molecular Probes) as described [16,17].
Proliferation Analysis by Ki67 Staining
Cellular proliferation was analyzed by immunohistochemical
staining of formalin-fixed tissues using a rabbit polyclonal anti-
Ki67 antibody. Ten randomly chosen sections from 5 animals per
group were used for analysis. The number of Ki67-labeled nuclei
in total 5000 hematoxylin-stained prostate epithelial cells was
quantified using an Axioplan 2 microscope.
Cell Culture and Transfection
LNCaP human prostate tumor cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in RPMI1640 media (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS and 1% Penicillin/Streptomycin at
37uC under 5% CO2. The hTERT-immortalized normal prostate
epithelial cells (PrEC) cells were generously provided by Dr.
William Hahn (Dana-Farber Cancer Institute, Boston, MA) [18]
and maintained in PrEGM medium. Cells were grown to ,80%
confluence, at which time they were transiently transfected with
small interfering RNAs (siRNAs) or gene expressing constructs. To
silence ATF3 expression, cells were transiently transfected with
ATF3 ON-TARGETplus SMARTpool siRNAs as well as 4
independent ATF3 siRNAs duplexes (Dharmacon Inc., Chicago,
IL) using Nucleofector (Amaxa, Walkersville, MD). For ATF3
overexpression, an ATF3 construct (or empty vector control) was
used for transient transfection of LNCaP cells.
Measurement of Cholesterol Level
Tissues or cells were finely minced in PBS on ice, membranes
were isolated as described [19], and cholesterol levels were
determined after lipid extraction using the Infinity Cholesterol
Liquid Stable Reagent (Thermo Electron Corp., Waltham, MA).
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LNCaP cells were incubated in control medium or cholesterol-
depletion medium for 18 h.
After trypsinization, cells were resuspended in PBS containing
2% FBS, and fixed in absolute ethanol at 4uC for 1 h. Cells were
resuspended in 50 mg/mL propidium iodide staining solution and
subjected to flow cytometry using a FACSCalibur flow cytometer
(BD Biosciences). The apoptotic population of cells (sub-G0/G1)
was calculated by using CellQuest Pro (BD Biosciences).
RNA Extraction
Total RNA was purified from prostate lobes or cultured cells
using a Qiagen RNEasy tissue extraction kit (Qiagen Inc.,
Valencia, California). RNA concentration was measured using a
Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Will-
mington, DE).
Microarrays and Data Analysis
Reverse transcription of total RNA and subsequent steps for
sample probe preparation, microarray hybridization, washing and
scanning of microarrays were performed by following a standard
Affymetrix protocol at the Dana-Farber Cancer Institute micro-
array core facility. Oligo-based Mouse Genome 430A 2.0 Arrays
(Affymetrix, for mouse microarray) or Human Genome U133A
2.0 Array (NuGEN V2, for LNCaP microarray) were used,
respectively. For the mouse array experiment, two biological
repeats were performed, while for the human array experiment,
single samples were performed across a time course. Data
normalization and summarization of expression values for each
probe were calculated using the gcRMA method. We used the
annotations of probesets that were provided by the Affymetrix
website. All raw microarray data discussed here are deposited and
available at Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) under the accession number GSE25500.
For the LNCaP data set, we then identified the differentially
expressed genes (DEGs) as the genes with absolute log2-fold-
changes with respect to CDM/time 0.0.585 (i.e. 1.5 fold). For the
Hyper diet data, we used the following integrative hypothesis
testing method: 1) we performed two-tailed T-test and log2-
median-ratio tests; 2) false discovery rates (FDRs) were computed
using all possible randomization experiments for the individual
statistical tests using Storey’s method [20]; 3) the FDRs from the
individual statistical tests were combined to result in the overall
FDRs using Stouffer’s method [21]. The DEGs were selected as
the ones whose overall FDRs were ,0.05 and also absolute values
fold changes .0.585. To integrate differential expression patterns
of the DEGs in mouse and human, we used the ontology
information obtained from the Mouse Genome Informatics (MGI)
database (ver. 4.4). We searched for Gene Ontology Biological
Processes (GOBPs) and known pathways that were statistically
enriched by the DEGs using the DAVID software [22].
Network Modeling
We constructed a hypothetical network model using the 265
DEGs altered in both the hypercholesterolemic diet and CDM
conditions. Information on protein-protein and protein-DNA
interactions was gathered from the Kyoto Encyclopedia of Genes
and Genomes (KEGG) and NCBI databases. We generated an
initial network using the first neighbors of the 265 DEGs based on
the interaction data. The initial network was then reduced to
generate a subnetwork by removing the first neighbors of the
DEGs that do not contribute to connecting DEG nodes. Finally,
the nodes were grouped based on functional similarities based on
GOBPs. To identify key central regulators among the DEGs, we
computed ‘degree centrality’ of each regulator in the network [23].
A DEG regulator with high degree of centrality is considered a
critical component that can regulate biological processes in the
network [24].
Reverse Transcription and PCR
Primers for RT-PCR were designed using Mac Vector and were
ordered from Integrated DNA Technologies (Coralville, IA). The
cDNA amplification was performed using Invitrogen Platinum
Blue PCR Supermix (Carlsbad, CA).
Cell Lysis and Western Blot Analysis
Tissue or cells were finely minced in PBS on ice and whole cell
lysates were prepared in SDS-containing lysis buffer (62.5 mM
Tris pH 7.4, 10% glycerol, 1% SDS and protease inhibitor
cocktail) or in NP-40-containing lysis buffer (1% Nonidet P-40,
50 mM Tris pH 7.4, 10 mM NaCl, 1 mM NaF, 5 mM MgCl2,
0.1 mM EDTA, 1 mM PMSF and protease inhibitor cocktail).
After centrifugation at 12,0006g for 15 min to remove debris,
protein concentration was determined by microBCA (Pierce/
Thermo Scientific). Equal amounts of the lysates (20 mg) were
subjected to SDS-PAGE and transferred onto nitrocellulose
membranes for western blot analysis. Blotting signals were
normalized by reprobing blots with anti-b-actin antibody, followed
by densitometry for quantification.
Promoter Luciferase Assay
Luciferase reporter constructs with ATF3 promoter, wild type
cyclin D1 promoter, or ATF3 binding mutant cyclin D1 promoter
constructs were used for transient transfection of LNCaP or PrEC.
Luciferase activity was measured in cell lysates using a luciferase
assay kit (Promega, Madison, WI). Total protein was used for
normalization. All experiments were carried out in triplicate and
repeated 3 times using different preparations of plasmids.
Cell Proliferation Assay
LNCaP or PrEC were plated onto 6-well culture plates at a
density of 1610
3 cells per well in standard growth medium. The
following day cells were serum-starved for 16 h followed by
treatment with the indicated medium: SF (serum free), CDM
(cholesterol-depleted medium) or control medium. Cell prolifera-
tion rate was determined by crystal violet staining. Briefly, cells
were stained with crystal violet solution and quantified by
dissolving stained cells in 10% acetic acid solution. Colorimetric
analysis was performed by measuring absorbance at 570nm.
Assessment of Inflammation
The inflammatory infiltrate detected in the peri-prostatic
adipose tissue of H&E stained slides was subjected to semi-
quantitative scoring as follows: 0 (absent; no infiltrate), 1 (mild;
focal, scattered monocytoid cells), 2 (moderate; monocytoid cells
organized in small lymphoid follicles), and 3 (severe; monocytoid
cells organized in large lymphoid follicles).
Statistical Analysis
P-values were calculated using unpaired Student’s t-tests or two-
way ANOVA for simple comparisons. P,0.05 is considered
statistically significant.
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PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e39448Figure 1. Effect of dietary cholesterol on circulating and prostatic tissue cholesterol levels in vivo. Male SCID mice were fed for 4 months
(m) either a Hyper or a Normo diet, and circulating as well as prostatic tissue cholesterol levels determined. (A) Hyper diet enhances prostatic
proliferation. 10 randomly selected sections per group were used for analysis with proliferating cells determined by Ki-67 staining. Ki-67 positivity is
shown as average 6 SD (n=10/group) of positive cells in a total of 5000 prostate epithelial cells. (B) Circulating cholesterol levels. Serum
cholesterol levels were determined and are plotted as cholesterol (mg/dL) vs. diet group 6 SD (n=15/group) (C) Cholesterol levels of prostate
membrane. Cholesterol was extracted from membrane fractions prepared from prostate tissue and cholesterol levels determined by Infinity assay.
Data are presented as cholesterol (mg/mg tissue) vs. group 6 SD (n=3/group). *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0039448.g001
Figure 2. Cholesterol depletion reduces cellular cholesterol levels and inhibits proliferation without inducing apoptosis. (A–B)
Cholesterol depletion reduces cellular proliferation of LNCaP (A) and PrEC cells (B). Cell proliferation was determined at the indicated times by crystal
violet staining. Data are plotted as cell proliferation (A.U., absorption units) vs. time (days) 6 SD (n=5). (C) Incubation in cholesterol-depleted
media (CDM) reduces cellular cholesterol levels. LNCaP cells were incubated in control media (RPMI 10% FBS) or CDM for 18 h. Cholesterol
level data are presented as percent cholesterol vs. treatment 6 SD (n=3). (D) Cholesterol depletion does not induce apoptosis. LNCaP cells
were treated in control media or CDM for 18 h and were analyzed for levels of apoptosis by flow cytometry. Cell populations at Sub-G0/G1 are
apoptotic. *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0039448.g002
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Molecular Responses to Variations in Cholesterol Level
In order to investigate the nature of the response of the normal
mouse prostate to chronic changes in circulating cholesterol levels,
we made 7–8 wk old male C57BL/6 and severe combined
immunodeficient (SCID) mice (which lack T and B cells)
hypercholesterolemic (the ‘‘Hyper’’ condition), and compared
them with mice maintained at normal cholesterol levels (the
‘‘Normo’’ condition) for 4 months using an isocaloric diet
procedure developed by our group [7]. Circulating testosterone/
DHT, insulin levels, prostate size and prostate volume were not
statistically different between the 2 groups (Hyper vs. Normo), and
these diets did not cause weight gain/loss or liver dysfunction (data
not shown). Histological examination of prostate tissue from
immune intact C57BL/6 mice revealed extensive, dense inflam-
matory infiltrates in the periprostatic adipose tissue (Fig. S1), but
not in prostate parenchyma, in the Normo group (not shown). In
order to detect primarily parenchymal, instead of inflammatory,
responses to changes in circulating cholesterol, we used SCID
mice in subsequent RNA expression profiling experiments in
which circulating cholesterol was manipulated.
SCID mice fed the hypercholesterolemic (Hyper) diet demon-
strated ,3 fold increased proliferation in prostate tissues,
compared to the Normo condition, based on Ki67 staining index
(Fig. 1A). As expected, Hyper mice showed ,2.5 fold increase in
serum cholesterol (Fig. 1B). Cholesterol level in the membrane
fraction of mouse prostate tissues was also increased .1.5 fold in
the high cholesterol cohort (Fig. 1C), indicating that elevated
circulating cholesterol affects membrane lipid composition of
prostate cells in vivo.
To characterize molecular responses to the elevation in
circulating cholesterol, gene expression profiling of SCID mouse
prostate tissue was performed using Affymetrix mouse 430A.2
microarrays. We identified 1815 differentially expressed genes
(DEGs) with a false discovery rate (FDR),0.05. 877 DEGs were
upregulated and 938 were downregulated in the ventral prostate
(VP) lobes from the Hyper vs. Normo groups. GOBP and KEGG
pathway enrichment analysis (Table S1) demonstrated that the
upregulated genes were mainly involved in cellular processes
related to cell proliferation, inflammation, and chemotaxis
(p,0.05), while the downregulated genes were related to
biosynthesis and cell adhesion, as well as protein folding, transport,
localization, and degradation. Genes involved in inflammation/
chemotaxis and cell proliferation/apoptosis suppression were
largely upregulated (Table S1), consistent with the increased
proliferation observed by direct examination of tissue (Fig. 1A).
As an alternative approach to testing the effect of altered
cholesterol availability on prostate cells, cholesterol levels were
reduced in cultured human prostate cells using a published
procedure employing acute exposure to cholesterol-depleted
medium (hereafter referred to as CDM) [25]. In addition to using
LDL-deficient serum, this medium includes an HMG-CoA
reductase inhibitor to reduce endogenous cholesterol synthesis,
along with a titrated amount of mevalonic acid to prevent
depletion of non-sterol end products, e.g. isoprenoids. Treatment
with CDM suppressed proliferation of both LNCaP prostate
cancer cells (Fig. 2A) and normal human prostate epithelial cells
(PrEC) (Fig. 2B), consistent with the essential role of cholesterol in
cell proliferation. Incubating LNCaP cells in CDM resulted in a
<60% reduction in intracellular cholesterol (Fig. 2C), but no
cytotoxicity and no evidence of apoptosis above baseline was
detected (Fig. 2D).
Gene expression profiling of LNCaP cells exposed to CDM
conditions for 0, 3 or 16 h was performed using Human Genome
U133A 2.0 microarrays. We identified 217 and 2477 DEGs in the
3 and 16 h conditions, respectively (See Materials and Methods;
Fig. S2A and S2B). Analysis of gene expression patterns revealed 8
distinct groups (Fig. S2B), with the largest groups of DEGs (groups
4 and 5) not differentially expressed until 16 h after initiation of
the experiment, while the second largest groups (groups 1 and 8)
were differentially expressed from 3 h and continued to 16 h.
Functional enrichment analysis of DEGs (Table S2) shows that the
up-regulated genes induced by CDM treatment were mainly
involved in cellular processes related to the folding, transport,
localization, and degradation of proteins (p,0.05), while the
down-regulated genes were involved in processes related to cell
cycle progression, cell proliferation, inflammation, and immune
response, consistent with the finding that CDM medium
suppressed rates of cell growth (Fig. 2A). The results in Tables
S1 and S2 indicate that similar cellular processes were affected by
hyper- and hypocholesterolemic (Hypo) conditions, but in opposite
directions.
A Cholesterol-sensitive Network
The overlap in the gene expression response to hypercholester-
olemia in the mouse prostate and to CDM in LNCaP cells
prompted us to integrate both data sets. We identified 449 genes
altered in the 2 conditions (Fig. S3). These 449 DEGs were
categorized into 4 groups based on the expression patterns
between Hyper mouse prostates and CDM-treated LNCaP cells.
This analysis narrowed the genes of interest to 265 (Clusters 2 and
3, Fig. S3A), whose expression levels were significantly altered in
opposing directions in the 2 experimental settings. Using this gene
set, we then constructed a hypothetical cholesterol-sensitive
network to obtain a deeper and broader understanding of the
genes/proteins underlying the prostatic response to changes in
cholesterol.
The network (Fig. 3A) includes several interesting modules
(clusters of functionally related genes based on GOBPs), including
modules related to carbohydrate metabolism, inflammation, cell
cycle regulation, cell migration, chromosome remodeling, RNA
splicing, vesicular transport and steroid biosynthesis. The node
and node boundary colors in Fig. 3A represent gene expression
changes induced by hypercholesterolemia in vivo and by CDM
treatment in vitro, respectively (See Methods or Figure legends). To
Figure 3. Network modeling of the cholesterol-responsive genes. (A) A provisional network was generated from integration of two
microarray data sets. Node color represents increases (red), no significant changes (yellow), and decreases (green) in gene expression in murine
prostate tissue after cholesterol alteration as ascertained by cDNA microarray. Changes in RNA expression levels of the corresponding nodes in LNCaP
cells are shown as colored node boundaries (donut shape) and the color represents increases (red), no significant change (yellow), and decreases
(green) in gene expression under CDM conditions compared to control. Arrows indicate direct activation, T-shaped lines direct repression, dashed
arrows indirect activation, and lines physical interaction. (B) Gene expression under Normo and Hyper conditions (in vivo). To verify in vivo
microarray data obtained from SCID experiments, mRNA levels of the indicated genes were determined. GAPDH expression was used to normalize
gene expression. Error bars represent SD (n=3). (C) Gene expression under Control and Cholesterol-depleted conditions (in vitro). LNCaP
cells were incubated in CDM for 0, 3 or 16 h, and mRNA levels of the indicated genes were measured by RT-PCR analysis to validate cDNA microarray
data. Error bars represent SD (n=3). *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0039448.g003
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differential expression of a total of 8 genes, which we considered
representative of all functional categories, in the in vivo Hyper vs.
Normo conditions or in the cull culture CDM vs. normal medium
conditions. Two genes with a high degree of centrality (See
Materials and Methods), ATF3 (activating transcription factor 3, a
mammalian ATF/CREB family transcription factor) and a known
ATF3 target, ID1 (DNA-binding protein inhibitor 1), were tested
under both conditions (Figs. 3B and 3C). As predicted from the
microarray data, hypercholesterolemia reduced the mRNA levels
of ATF3 as well as ID1, and enhanced those of C3 (apolipoprotein
C3), S100A (S100 calcium-binding protein A) and IFI44 (gamma-
interferon-inducible protein 44) (Fig. 3B). Also consistent with the
microarray findings, in the cell culture setting mRNA levels of
ATF3, ID1, ID2, CDK2 (cyclin-dependent kinase 2), and VEGFC
(Vascular endothelial growth factor C) were up- (ATF3, ID1 and
ID2) or down-regulated (CDK2 and VEGFC) in response to
CDM treatment (Fig. 3C). These findings support the validity of
the network model shown in Figure 3A.
ATF3: a Central Node in the Prostatic Response to
Changing Cholesterol Levels
To identify one or more ‘‘key’’ regulators of the prostatic
response to cholesterol, we performed the following analysis. We
selected genes for regulatory proteins (e.g. transcription factors,
signaling molecules) from the 265 consistently altered DEGs. For
each regulator, we then tallied its degree of centrality, based on the
number of known DEG interactors (See Materials and Methods).
The goal was to identify the key regulators with the largest degree
of centrality in the network. This analysis identified ATF3 as one
such potential key regulator because it has known targets ICA1
(islet cell autoantigen 1), ID1, TCF12 (transcription factor 12),
Figure 4. ATF3 expression coincides with reduced cholesterol. (A) RT-PCR analysis in vivo. ATF3 levels are reduced in all prostatic lobes
from Hyper mice, compared to those from the Normo group (AP=anterior prostate; VP=ventral prostate; DLP=dorsal prostate). (B) Immunoblot
analysis. Immunoblot of PrEC lysates showed induction of ATF3 protein by CDM (left panel) and by b-cyclodextrin (right panel). MG132, a
proteasome inhibitor, also increased ATF3 expression. (C) Immunofluorescence analysis. Induction of ATF3 protein by CDM in LNCaP cells as
shown by IF. LNCaP cells were treated with CDM for 18 h, stained with anti-ATF3 antibody and nuclei were counterstained with DAPI (left panel:
ATF3; middle panel: DAPI; right panel: overlay). (D) RT-PCR analysis. ATF3 mRNA levels in LNCaP cells treated with CDM were normalized to levels
of GAPDH. RT-PCR analysis shows induction of ATF3 mRNA levels by CDM. (E–F) Promoter reporter analysis. A full-length ATF3 promoter was
cloned into a luciferase reporter vector and transfected into LNCaP (D) or PrEC (E). Cells were then incubated in Control and CDM medium. ATF3
promoter activity was plotted as arbitrary units (6 SD) after normalization with total protein concentration.
doi:10.1371/journal.pone.0039448.g004
ATF3 Regulates a Prostate Cholesterol Network
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e39448TBL1X (transducin (beta)-like 1X-linked) and RNF14 (E3
ubiquitin-protein ligase) in at least 4 distinct modules (vesicular
transport, cell proliferation, chromosome remodeling and RNA
splicing) in the cholesterol-sensitive network.
ATF3 has been reported to participate in both cell proliferation
and immunity [26,27], and due to alternative splicing functions,
can act as both an activator and repressor of gene transcription
[28–32]. As a further test of the network model, we focused
specifically on ATF3 and its sensitivity to cholesterol. RT-PCR
analysis using three prostatic lobes (anterior prostate, AP; ventral
prostate, VP and dorsolateral prostate, DLP) demonstrated that
ATF3 gene expression levels were significantly decreased in the
Hyper, compared to the Normo condition (Fig 4A). Consistent
with these downward changes seen in hypercholesterolemia,
expression of the ATF3 protein was induced in a time-dependent
manner in both PrEC and LNCaP cells in response to cholesterol
lowering in CDM (Figs. 4B and 4C). ATF3 was also acutely
induced in response to rapid depletion of membrane cholesterol
with methyl-b-cyclodextrin (b-CD), a cholesterol-absorbing re-
agent (Fig. 4B, right panel). ATF3 mRNA level was increased
approximately 2.5-fold after 3 h of CDM treatment and this
increase was retained for at least 30 h (Fig. 4D). Assessment of the
responsiveness of the ATF3 promoter to cholesterol by luciferase
reporter assay showed that CDM evoked ATF3 transcriptional
activation in LNCaP (Fig. 4E) as well as PrEC (Fig. 4F), consistent
with the mRNA and protein data.
In order to test whether adding endogenous cholesterol reverses
the induction of ATF3 expression upon cholesterol depletion,
human PrEC were incubated in CDM with and without soluble
cholesterol (Fig. 5A). The presence of 10 mg/ml water-soluble
cholesterol inhibited CDM-induced ATF3 expression approxi-
mately 40% (Fig. 5A). A cholesterol containing liposome
preparation (SDC) [33], containing 33 mol% each of sphingomy-
elin, 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cho-
lesterol, raised cholesterol level in LNCaP cells (Fig. 5B) and
reversed ATF3 upregulation induced by CDM treatment (Fig. 5C).
Significantly, this manipulation reversed the inhibition of cell
proliferation induced by CDM (Fig. 5D).
These data show that ATF3 expression is regulated by
cholesterol level both in normal immortalized prostate epithelial
cells and in androgen-dependent prostate cancer cells. Moreover,
the inverse correlation of ATF3 level and cell proliferation suggests
that altered ATF3 may mediate the effect of cholesterol on
regulating cell proliferation.
ATF3 Regulates Prostate Cell Proliferation
We next performed functional studies in LNCaP cells to assess
the biological role of ATF3. Enforced expression of ATF3
inhibited cell proliferation, an effect that was reversed by ATF3-
targeted RNA interference (RNAi) (Fig. 6A). Conversely, knock-
down of ATF3 using RNAi increased cell growth (Fig. 6B),
suggesting that the endogenous protein is growth suppressive.
Figure 5. Cholesterol reduces ATF3 expression in prostate epithelial cells. (A) PrEC were incubated in CDM for 18 h and then water-soluble
cholesterol (cholesterol loaded cyclodextrin) was added to the medium in a dose dependent manner (0, 1, 5, and 10 mg/ml) for 3h. After immunoblot
analysis, band intensities were normalized to b-actin and fold changes are shown. (B) Cholesterol-containing liposomes increase cholesterol
level. LNCaP cells were incubated in CDM for 18 h in the absence or presence of cholesterol containing liposomes (SDC (33% (mol)
sphingomyelin+DOPC+cholesterol) [33]. Data are plotted as percent cholesterol level (6 SD) (C) Cholesterol containing liposomes reverse
ATF3 protein induction by CDM. LNCaP cells were transiently transfected with control siRNA (siCon) or siATF3. 48 h after transfection, cells were
incubated in CDM for 18 h in the absence or presence of SDC. ATF3 protein levels were measured by immunoblot analysis. (D) Enhanced
proliferation by cholesterol containing liposomes. LNCaP cells were incubated in CDM in the absence or presence of SDC [33]. After 3 d, cell
proliferation was measured. Data are plotted as cell proliferation (A.U., absorption units) vs. time (days) 6 SD (n=3). Con, serum containing growth
medium; CDM, cholesterol depletion medium; SDC, cholesterol containing liposome preparation. *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0039448.g005
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requiring CDM treatment for visualization (Fig. 6B, upper panel).
To rule out the off-target effects of siRNAs, 4 independent ATF3
siRNAs were tested. Consistent with results using the ATF3
siRNA pool, cell proliferation was enhanced when ATF3
expression was depleted by the 4 individual ATF3 siRNAs
(Fig. 6C).
Notably, the increased ATF3 level (.1.5 fold) in response to
CDM coincided with reduced cyclin D1 expression (<0.5 fold
compared to time 0) (Fig. 6D). Because cyclin D1 plays an essential
role in the cell cycle transition from early to mid-G1 phases, we
asked whether there is a functional link between ATF3 and cyclin
D1 in the context of cell proliferation. Fetal bovine serum (10%)
raised cyclin D1 expression as expected in a time-dependent
manner in serum-starved control cells. ATF3 knockdown by RNAi
increased cyclin D1 levels even in the absence of serum stimulation
(Fig. 6E). Cyclin D1 promoter-driven expression of luciferase was
also enhanced in response to serum, and was almost completely
suppressed by ATF3 overexpression (Fig. 6F). To determine
whether cyclin D1 mediates proliferative effects of ATF3 in
response to cholesterol alterations, we compared the response of
the wild type cyclin D1 (WT) promoter, and an identical promoter
with the ATF3-binding site inactivated by mutation (MUT), after
incubation in two control conditions (medium 6 FBS) or CDM.
Figure 6. ATF3 is a negative regulator of cyclin D1 and cell proliferation. (A) Enforced AFT3 expression reduces cell proliferation.
LNCaP cells were transiently transfected with an ATF3 expression construct, a vector alone control, or with the AFT3 expression construct + ATF3
siRNAs. Proliferation rate was measured at the indicated times. ATF3 expression levels were verified by immunoblot (upper panels). Data are plotted
as cell proliferation (fold) vs. condition (Vec, ATF3, ATF3+siATF3) 6 SD (n=3). (B–C) Knockdown of ATF3 increases cell proliferation. LNCaP
cells were transiently transfected with siATF3 (or siCon) and the number of cells at day 0 (grey bars) & day 3 (black bars) were measured. Four
independent ATF3 siRNAs (siATF3-1, -2, -3, and -4) were transiently transfected, and cell numbers were determined at day 3. Data are plotted as cell
proliferation (fold) vs. condition 6 SD (n=3). (D) Effect of cholesterol depletion on ATF3 and cyclin D1 expression. LNCaP cell were treated
in serum free media (SF; grey bars) or with CDM (black bars) for 16 h and the level of ATF3 and cyclin D1 were determined. Data were normalized to
b-actin from the same blots. Immunoblot data are representative of the immunoblot result used in densitometry. Data are plotted as expression level
(fold) vs. condition 6 SD (n=3). (E) ATF3 regulates cholesterol depletion-induced cyclin D1 expression (immunoblot analysis). LNCaP
cells were transiently transfected with siATF3 (or siCon). After serum starvation for 16 h, cells were stimulated with 10% serum for the indicated times.
Immunoblot analysis was performed to determine cyclin D1 expression in ATF3 deficient cells. (F) ATF3 regulates cyclin D1 expression
(promoter reporter analysis). LNCaP cells were transfected with promoter construct of cyclin D1 containing a luciferase reporter and followed by
additional incubation with 6 serum for 6 h. Data are plotted as promoter activation (fold) vs. condition 6 SD (n=3). (G) Promoter activation of
cyclin D1 upon cholesterol alteration requires ATF3 binding on promoter region (promoter reporter analysis). LNCaP cells were
transfected with a luciferase construct of a wild type (WT) or an ATF3 binding site mutated cyclin D1 (MUT) promoter. Promoter activity was
measured 6 h after treatment with various conditions (6FBS or CDM). Data are plotted as promoter activation (fold) vs. condition 6 SD (n=4). All
experiments were performed a minimum of 3 times. *p,0.05, **p,0.01 (Student’s t-test).
doi:10.1371/journal.pone.0039448.g006
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was diminished when the ATF3 binding site was mutated (Fig. 6G).
These results imply that ATF3 downregulation under conditions
of hypercholesterolemia may activate cyclin D1 expression and
lead to enhanced cell proliferation.
Influence of Cholesterol on ATF3 Expression and
Inflammatory Infiltrates
In order to further investigate whether circulating cholesterol
levels alter ATF3 expression in vivo in immune-intact animals, 7–
8 wk old male C57BL/6 mice (n=18/group) were maintained
under Hypo, Normo or Hyper conditions for 4 months. There
were no significant differences in weight, insulin level, circulating
testosterone/DHT level, and no detectable liver dysfunction, in
the 2 groups. The Hypo diet resulted in circulating cholesterol
levels about 60% lower than the Hyper diet (p,0.05), and the 3
diet regimens resulted in 3 distinct average cholesterol levels
(Fig. 7A). To assess the effect of circulating cholesterol level on
ATF3 expression, we measured ATF3 mRNA and protein levels
in C57BL/6 mouse prostate tissue under Hypo, Normo or Hyper
conditions. Consistent with the findings presented above, ATF3
mRNA (Fig. 7B) and protein (Fig. 7C and 7D) were markedly
reduced, seemingly in a step-wise manner, with increasing
cholesterol.
Prostate tissue from Hypo mice showed evidence of substantially
decreased Ki67 staining (Fig. 8A) and lymphomononuclear cell
accumulation (Fig. 8B), in comparison to the Normo (not shown)
and Hyper groups, indicating that cholesterol reduction may
reduce prostatic inflammation. In the Normo and Hyper groups,
inflammatory cell clusters (L) were found closely associated with
nerve tracts (N) and blood vessels (yellow arrows) in Hyper animals
(Fig. 8C(i)). The presence of lymphomononuclear infiltrates was
negligible in the Hypo condition (data not shown). IHC analysis
using marker proteins of immune cells (CD45, a general marker
Figure 7. ATF3 expression level is associated with cholesterol level in vivo. Male C57BL/6 mice were fed Hypo, Normo, or Hyper diets for 4
months. (A) Circulating cholesterol levels. Serum cholesterol levels are plotted as cholesterol (mg/dL) vs. diet group 6 SD (n=18/group). (B) RT-
PCR analyses of ATF3 expression. The expression levels of ATF3 mRNA and protein were compared in ventral prostate (VP) from male C57BL/6
mice in Hypo, Normo or Hyper conditions by quantitative densitometry. Data are plotted as mRNA level (arbitrary unit) vs. condition 6 SD (n=3).
GAPDH expression was used to normalize gene expression. (C) Immunohistochemical analysis of ATF3 expression. Sections of VP tissues from
mice in Hypo, Normo or Hyper groups, stained with anti-ATF3 antibody. Representative images of Hypo and Hyper are shown. (D) Immunoblot
analyses of ATF3. Immunoblot data are presented as box and whisker plots of ATF3 expression levels (arbitrary units) vs. group. Bottom of
red=median of lower half of the data. Top of yellow=median of upper half of the data. Intersection of red and yellow=median. Green=average.
Vertical bars extend to maxima and minima (n= 18/group). *p,0.05 (two way ANOVA and Student’s t-test). Representative western blot data are
shown (right).
doi:10.1371/journal.pone.0039448.g007
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monocytoid cells in the infiltrates are a mixture of B and T cells,
with a predominance of B lymphocytes (Fig. 8C(ii)).
Discussion
In this study, we sought to gain insight into the mechanism by
which the normal prostate responds to changes in cholesterol level
in the microenvironment. We took a systems approach of
identifying a cholesterol-responsive gene set and constructing a
signaling network. We then tested this network using a series of
independent approaches. We used an isocaloric diet method that
allows isolation of cholesterol level as a variable independent of
energy effects, animal weight variation, level of visceral fat or
changes in circulating androgen [7]. Direct examination of
prostate tissue from mice kept under chronic hypercholesterolemia
demonstrated increased cell proliferation and under hypocholes-
terolemic conditions showed suppressed inflammatory cell infil-
tration. These findings suggest that circulating cholesterol may
trigger pathophysiological changes in the prostate, and that
lowering cholesterol may inhibit such changes. In vitro cholesterol
depletion experiments showed that cell proliferation is inhibited by
insufficient cellular cholesterol. By integrating unbiased gene
expression data from the in vivo and in vitro experiments, we
identified a network of cholesterol-regulated genes in the prostate.
Further analysis indicated that the transcription factor ATF3 is
likely to be an important node in this network. To our knowledge,
this is the first systematic study of the signaling mechanisms in the
prostate affected by changes in cholesterol levels.
ATF3 is a 21kDa leucine zipper (bZIP) transcription factor that
belongs to the ATF/CREB protein family. ATF3 mRNA levels
are low or undetectable in most tissues under most conditions, but
are induced by a variety of environmental cues, including
cytokines, xenotoxic agents and physiological stresses [26]. ATF3
has been identified as a suppressor of innate immunity, viral
immunity, and allergic inflammation [26,34–38]. ATF3 suppresses
LPS-induced expression of interleukin (IL)-6 and IL-12 in
macrophages by working in conjunction and in opposition to
Rel (an NFkB subunit), an activator of IL-6 and -12 genes [37].
ATF3 is also activated in the lungs of mice after allergen challenge,
Figure 8. Hypocholesterolemia suppresses prostatic inflammation. (A) Proliferative index. Proliferating cells were counted by Ki-67
staining as described in Materials and Methods. Data are plotted as Ki-67 positive cells vs. condition. (B) Inflammation score. Infiltrating cells were
scored as described in Materials and Methods. Data are plotted as inflammation score vs. condition. (C-i) VP lobes from male C57BL/6 mice in
the Hyper condition. Lymphoid cell populations (L) infiltrating periprostatic adipose tissue adjacent to nerves (N) and blood vessels were observed
in the Hyper condition (yellow arrows). Two representative fields are shown. (C-ii) IHC staining with anti-CD45 (1:150) and anti-CD3 (1:200) show
inflammatory infiltrates observed in the Hyper condition are a mixture of B and T cells. Spleen tissue from male C57BL/6 mice was used as a positive
control for IHC and protocol optimization. Blue arrowhead, adipose tissue; Red arrowhead, a prostatic acinus.
doi:10.1371/journal.pone.0039448.g008
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4, IL-5, IL-13 and other CCL (b-chemokine ligand) chemokine
genes that mediate immune cell infiltration to pulmonary tissue.
Consequently, ATF3-deficient mice exhibit increased airway
hypersensitivity including enhanced eosinophilia [36]. Together,
those studies suggest that ATF3 regulates inflammatory responses.
As a transcriptional repressor of cyclin D1, IRS (insulin
receptor substrate) 2, and ID1 expression in chondrocytes, mouse
embryonic fibroblasts, mouse pancreatic beta cells, and HaCaT
human skin keratinocyte cells, ATF3 functions as an anti-
proliferative factor [39–43]. In cancer cells, ATF3 has also been
identified as an inhibitor of Ras-stimulated tumorigenesis [43].
Those studies suggest that ATF3 induction correlates with cell
cycle arrest, growth inhibition, and/or apoptosis. In contrast,
ATF3 overexpression enhanced transcription of FN (fibronectin)-
1, TWIST (twist transcription factor)-1 and Slug in MCF10CA1
breast cancer cells [44], and led to increased proliferation of
DU145 prostate cancer cells [45]. Moreover, targeting ATF3 for
knockdown inhibits cell adhesion and invasion capability in
HT29 human colon cancer cells [46]. ATF3 increased apoptosis
in untransformed MCF10A mammary epithelial cells, while it
inhibited apoptosis in MCF10A breast tumor cells [44]. These
discrepancies in function suggest that the biological role of ATF3
is highly dependent on physiologic conditions. The role of ATF3
in malignancy cannot be generalized as either being oncogenic
or tumor suppressing; it exhibits properties of both functional
classes. This duality of function has been explained as a
consequence of: (a) cellular context; (b) post-translational
modifications; (c) interacting proteins; (d) sub-cellular compart-
mentalization; and/or (e) differential complex formation of ATF3
homo- or heterodimers with other bZip proteins (e.g. c-Jun, Jun
B and Jun D).
Hypocholesterolemic mice exhibited substantially reduced levels
of inflammatory infiltrates in the prostate and relatively high
expression of ATF3. Similarly, ATF3 mRNA level was rapidly
increased by depriving cells of cholesterol in vitro, an effect that was
sustained for at least 30 h (Fig. 4C). These data could be evidence
for suppression by high cholesterol of a feedback regulatory
mechanism that inhibits prostatic inflammation, although the
present data do not provide a mechanistic explanation for how
altered ATF3 expression might affect immune cell infiltration.
One possibility is that chronic hypercholesterolemia may activate
prostatic cells or/and adipocytes, through regulation of ATF3
levels, to secrete chemo-attractants (e.g. cytokines and chemotactic
adipokines) that recruit immune cells.
Notably, dense inflammatory infiltrates were found adjacent to
nerves, suggesting the possibility that prolonged high cholesterol
might lead to chronic pain. Recruitment of inflammatory cells into
nerve fibers has been identified as a likely source of visceral pain in
chronic pancreatitis, and painful ejaculation symptoms occur in 5–
31% of men with LUTS linked to BPH [47,48]. In light of our
present data, these observations, suggest the possibility that
prolonged high cholesterol may promote symptoms associated
with benign prostatic disease.
Our cholesterol sensitive network model revealed alterations in
an inflammatory signature in response to variation of cholesterol
level (Fig. 3A): Expression of S100A, C3 and IFI44 was increased
in the Hyper group, and decreased in the Hypo condition (Fig. 3).
Pathway analysis suggested that the immune/inflammation-
related genes were significantly enriched in the Hyper condition
(Table S1), suggesting an inflammatory response to high choles-
terol. Accumulating evidence has linked pathologic or premalig-
nant changes in the prostate with chronic inflammation. In
particular, most BPH tissues show evidence of a chronic
inflammatory reaction: (a) only 23% of prostate biopsies from
284 BPH patients were free of infiltrating inflammatory cells [49],
(b) the presence of inflammatory infiltrates in BPH tissues was
associated with increased rates of disease progression and elevated
risk of acute urinary retention (Medical Therapy of Prostatic
Symptoms (MTOPS) study), (c) human BPH stromal cells isolated
from surgical specimens express all of the toll-like receptors
(TLRs), which are central mediators of the innate immune system
[50]; and (d) a recent report of a BPH signaling network suggested
activation of inflammation through the TGFb-Smad2/3 signaling
pathway [51]. Chronic inflammatory infiltrates in BPH nodules
are mainly composed of T cells and macrophages [52–54], which
are recruited to the prostate by chemoattractants, including IL-6,
IL-8 and IL-15. In particular, IL-8 is highly expressed in BPH
specimens [55] and stimulates prostatic stromal and epithelial
growth during BPH progression [56].
In summary, we have identified elements of a cholesterol-
sensitive network in the normal prostate, thereby demonstrating
that the prostate senses and can mount a response to chronic
changes in circulating cholesterol. Because cholesterol-lowering
drugs of several types are in widespread use, further study of the
effects of cholesterol on the prostate and on lower urinary tract
function may uncover novel therapeutic strategies.
Supporting Information
Figure S1 Inflammation was observed in H&E staining
from C57BL6 mice, but not in SCID mice, in normal diet
condition.
(TIF)
Figure S2 Nucleotide microarray constructed gene
clusters based on expression pattern. LNCaP prostate cells
were treated with CDM for 0, 3 or 16h, and RNAs extracted were
used for RNA profiling. Gene expression levels of LNCaP cells at 3
or 16 h of treatment with CDM in comparison with untreated
cells are displayed. Green: downregulated genes; red: upregulated
genes in response to exposure to CDM. (A) Heat map showing
up- or down-regulated genes by cholesterol depletion.
(B) 8 clusters of transcripts were identified based on
expression pattern. The largest cluster containing prolifera-
tion-related genes showed a marked downregulation by CDM.
(TIF)
Figure S3 Integration of two DNA microarray datasets.
Two separately acquired microarray data from mouse prostate (in
vivo) and LNCaP cells (in vitro) were integrated to extract the
emerging cholesterol-sensing gene network in prostate cells in
response to cholesterol manipulation. (A) 449 genes were
identified in the Hyper and CDM conditions and categorized
into four groups: (1) both up, (2) up in one or the other, and (3)
both down. We focused the 265 genes that were significantly
altered in opposite directions by Hyper and CDM. (B) Heat
map showing the commonly found genes in Hyper and
Hypo (CLM) condition. Green, downregulated genes; Red,
upregulated genes compared to control.
(TIF)
Table S1 Enriched GOBP or KEGG terms by DEGs
affected by Hyper diet in the SCID VP lobe.
(TIF)
Table S2 Enriched GOBP or KEGG terms by DEGs
affected by CDM in LNCaP cells.
(TIF)
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